Retinitis Pigmentosa With or Without Situs Inversus (ARL2BP-Related Ciliopathy)

Disease: Retinitis Pigmentosa With or Without Situs Inversus MONDO ID: MONDO:0014186 · OMIM Phenotype: #615434 (RP66) · Gene: ARL2BP (16q13) Category: Mendelian (autosomal recessive)

Summary

Retinitis Pigmentosa With or Without Situs Inversus is a rare, autosomal-recessive ciliopathy caused by biallelic loss-of-function mutations in ARL2BP (ADP-ribosylation-factor-like 2 binding protein; also called BART), located at chromosome 16q13. ARL2BP was the first identified ARL2-GTP–specific effector protein, and it functions as an anchor/co-GEF for the ARL2 and ARL3 small GTPase cycle that governs the ciliary trafficking of lipid-modified phototransduction proteins and the assembly of the photoreceptor connecting-cilium axoneme. The disease was first defined in 2013 through homozygosity mapping and exome sequencing in two consanguineous families (PMID: 23849777), where one family combined retinitis pigmentosa (RP) with situs inversus, establishing the phenotypic hallmark that names the disorder.

The core disease process is degeneration of rod and cone photoreceptors producing classic retinitis pigmentosa (night blindness, progressive peripheral-then-central visual field loss, bone-spicule pigmentation, reduced/extinguished electroretinogram). Because ARL2BP is required for both primary/sensory cilia (photoreceptor outer segment) and motile cilia (embryonic node, sperm flagellum, airway), affected individuals may additionally show situs inversus totalis (in roughly half of patients — hence "with or without"), male infertility from oligo-/asthenozoospermia, and, in some cases, unilateral renal agenesis with renal microcysts and anosmia. This multisystem presentation places the disorder within the broader ciliopathy spectrum overlapping primary ciliary dyskinesia.

The condition is ultra-rare, reported in only a handful of largely consanguineous families worldwide, and is one molecular subtype of retinitis pigmentosa (overall prevalence ~1:4,000). There is currently no approved disease-modifying therapy; management is supportive (visual aids, low-vision rehabilitation, nutritional counseling, assisted reproduction for infertility, and airway management if primary ciliary dyskinesia features are present). The one FDA/EMA-approved retinal gene therapy (voretigene neparvovec, Luxturna) is specific to RPE65 and does not apply to ARL2BP. Diagnosis rests on ophthalmic phenotyping (ERG, OCT, fundus autofluorescence) plus next-generation sequencing, and an Arl2bp-knockout mouse faithfully recapitulates the retinal and ciliary phenotype, providing a validated preclinical model.

1. Disease Information

Retinitis Pigmentosa With or Without Situs Inversus is a Mendelian inherited retinal dystrophy in which progressive rod–cone degeneration (retinitis pigmentosa) occurs either in isolation or accompanied by laterality defects (situs inversus) and other ciliopathy features. It is a primary retinal ciliopathy — the underlying lesion affects the photoreceptor connecting cilium, a specialized primary cilium.

Key identifiers:

Synonyms / alternative names: Retinitis pigmentosa 66 (RP66); RP with situs inversus; ARL2BP-related retinitis pigmentosa; ARL2BP-related syndromic rod–cone dystrophy. Gene aliases: BART, BART1, RP66, RP82.

Information source type: The knowledge base entry is derived primarily from aggregated disease-level resources (OMIM, ClinVar, gnomAD, UniProt, NCBI Gene) supplemented by individual patient case reports describing single families or probands. It is not derived from large EHR cohorts, reflecting the disease's rarity.

2. Etiology

Primary cause — genetic. The disease is monogenic and Mendelian: biallelic (homozygous or compound-heterozygous) loss-of-function variants in ARL2BP cause the phenotype. There is no environmental, infectious, or acquired etiology. The original identification used a combination of homozygosity mapping and exome sequencing in two consanguineous families to establish ARL2BP as causative (PMID: 23849777): "we used a combination of homozygosity mapping and exome sequencing to identify mutations in ARL2BP, which encodes an effector protein of the small GTPases ARL2 and ARL3, as causative for autosomal-recessive RP (RP66)."

Genetic risk factors. The causal alleles are the pathogenic ARL2BP variants themselves (see Section 4). Because the disorder is recessive, consanguinity is the dominant risk-elevating factor — all originally reported families were consanguineous with homozygous variants. No modifier loci or susceptibility SNPs have been established for this ultra-rare disorder.

Environmental risk factors. None identified or expected for a monogenic recessive disorder. General retinitis-pigmentosa risk modifiers such as light exposure are not established for the ARL2BP subtype.

Protective factors. No genetic or environmental protective factors have been identified. Population constraint data (gnomAD: pLI ≈ 5.8×10⁻⁶, observed/expected LoF ≈ 0.79) indicate ARL2BP is tolerant of heterozygous loss of function — consistent with carriers being unaffected and disease requiring biallelic loss.

Gene–environment interactions. None documented. Disease expression is determined by genotype; the "with or without situs inversus" variability reflects the stochastic nature of left–right axis determination by motile nodal cilia rather than any environmental interaction.

3. Phenotypes

The phenotype is a syndromic rod–cone dystrophy with variable extra-ocular ciliopathy features. Core and associated phenotypes, with suggested HPO terms:

The multisystem triad of RP, situs inversus, and male infertility was explicitly described as novel in a Chinese patient (PMID: 36507858): "presenting with retinitis pigmentosa (RP), situs inversus totalis, and oligozoospermia … this a novel ARL2BP-associated phenotypic triad of RP, situs inversus, and male infertility." Renal and sperm involvement was further documented (PMID: 38649918): "a splice site variant in the ARL2BP gene causing situs inversus, asthenozoospermia, unilateral renal agenesis and microcysts."

Quality-of-life impact. The dominant burden is progressive vision loss, which impairs mobility, reading, driving, and independence and is a leading cause of visual disability; situs inversus totalis is generally asymptomatic; male infertility affects family planning. No disease-specific QoL instrument data exist for this ultra-rare subtype, but generic RP QoL measures (VFQ-25, low-vision instruments) apply.

Progression note. Course can be relatively slow — one patient retained useful residual vision at age 63 with slow progression over 5 years of follow-up (PMID: 38649918).

4. Genetic / Molecular Information

Causal gene: ARL2BP (GeneID 23568; OMIM 615407; HGNC:702; UniProt Q9Y2Y0), 16q13. NCBI summary: "This protein is considered to be the first ARL2-specific effector identified, due to its interaction with ARL2.GTP but lack of ARL2 GTPase-activating protein activity."

Pathogenic variants (all germline; no somatic involvement):

Variant classification (ACMG/AMP): ClinVar (accessed 2026) holds 146 ARL2BP variant records: ~11 Pathogenic and ~2 Likely pathogenic (predominantly splice-site and frameshift null alleles), ~10 VUS, ~8 likely-benign, and 1 with conflicting classifications. The predominance of null/loss-of-function pathogenic alleles supports a loss-of-function disease mechanism.

Allele frequency: Pathogenic alleles are extremely rare/absent in gnomAD, consistent with a recessive disorder confined to consanguineous or founder contexts. ARL2BP is LoF-tolerant in heterozygotes (pLI ≈ 5.8×10⁻⁶; o/e LoF ≈ 0.79).

Functional consequence: Loss of function. The p.Met45Arg missense allele mechanistically reduces ARL2 binding and abolishes ARL2BP localization to the photoreceptor basal body — a demonstrated pathomechanism rather than merely predicted (PMID: 23849777).

Modifier genes: None established. Epigenetic changes: Not implicated. Chromosomal abnormalities: None; the disease is caused by point/small variants, not large structural rearrangements (situs inversus here is a ciliary-motility consequence, not a chromosomal inversion despite the name).

5. Environmental Information

There are no environmental, lifestyle, or infectious contributors to this monogenic recessive disorder. No toxins, radiation, occupational exposures, dietary factors, or pathogens are implicated in causing or triggering ARL2BP-related disease. The only relevant "environmental" factor in a population-genetics sense is consanguineous mating, which increases the probability of homozygosity for rare recessive alleles.

6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic loss-of-function mutation in ARL2BP (splice, frameshift, or function-abolishing missense) → loss or dysfunction of ARL2BP protein.
2. Loss of ARL2BP → failure to anchor/localize at the ciliary basal body and cilium-associated centriole of photoreceptors (demonstrated: p.Met45Arg abolishes basal-body localization; ARL2 depletion displaces ARL2BP) (PMID: 23849777).
3. Mislocalized/absent ARL2BP → disrupted ARL2/ARL3 small-GTPase cycle (ARL2BP is the first ARL2-GTP-specific effector and acts as a co-GEF stabilizing active ARL3-GTP) (PMID: 33438581).
4. Impaired ARL3 activity → defective ciliary trafficking of lipid-modified (prenylated/myristoylated) phototransduction proteins via the RP2–ARL3–PDE6D axis, which chaperones prenylated cargo such as PDE6 and GRK1 into the outer segment (PMID: 25422369).
5. Branch A (sensory cilium / retina): cargo mistrafficking + axonemal defect → disorganized photoreceptor outer segments with vertically aligned disks, shortened axonemes, open B-tubule doublets, and loss of singlet microtubules (demonstrated in KO mouse) (PMID: 29718757) → progressive rod and cone death → retinitis pigmentosa (nyctalopia → field loss → central vision loss).
6. Branch B (motile cilia): the same ciliary/axonemal assembly defect in embryonic nodal cilia → randomized left–right axis determination → situs inversus (present in ~half of patients); in sperm flagella → oligo-/asthenozoospermia → male infertility; in airway cilia → potential primary-ciliary-dyskinesia-type respiratory features; in renal cilia → renal agenesis/microcysts; in olfactory cilia → anosmia.

Detail by category

• Molecular pathways: ARL2/ARL3 GTPase signaling; RP2–ARL3–PDE6D lipidated-cargo ciliary trafficking. ARL2BP moonlights in ARL2-dependent STAT3 nuclear translocation/transcriptional activity (UniProt Q9Y2Y0: "Together with ARL2, plays a role in the nuclear translocation, retention and transcriptional activity of STAT3.").
• Cellular processes: Ciliogenesis and ciliary maintenance; intraflagellar/ciliary protein transport; photoreceptor outer-segment disk morphogenesis; progressive photoreceptor apoptosis.
• Protein dysfunction: Loss of function via truncation (frameshift/splice) or loss of ARL2 binding + mislocalization (p.Met45Arg). GO molecular functions: GTPase regulator activity (GO:0030695), transcription coactivator activity (GO:0003713).
• Metabolic changes: Disrupted delivery of PDE6 (cGMP phototransduction cascade) impairs the visual cycle at the outer segment; broader metabolic changes not characterized.
• Immune involvement: None; not an autoimmune/inflammatory disease.
• Tissue damage mechanism: Structural failure of the connecting cilium/axoneme leading to outer-segment malformation and photoreceptor degeneration.
• Biochemical abnormalities: Failure of the ARL2BP→ARL3-GTP→PDE6D trafficking module; mislocalization of prenylated phototransduction enzymes.

Suggested GO / CL terms: BP — cilium assembly (GO:0060271), intraciliary transport (GO:0042073), photoreceptor cell maintenance (GO:0045494), determination of left/right symmetry (GO:0007368), regulation of GTPase activity (GO:0043087). CC — ciliary basal body (GO:0036064), photoreceptor connecting cilium (GO:0032391), centrosome (GO:0005813). CL — retinal rod cell (CL:0000604), retinal cone cell (CL:0000573), ciliated cell (CL:0000064), sperm (CL:0000019).

7. Anatomical Structures Affected

Organ level (primary): Eye — retina, specifically the photoreceptor layer (UBERON:0000970 eye; UBERON:0000966 retina; UBERON:0001789 photoreceptor layer). Secondary/associated organs: thoraco-abdominal viscera (laterality reversal in situs inversus — heart, lungs, liver, spleen, stomach mirror-imaged), testis/sperm (male reproductive system), kidney, olfactory epithelium.

Body systems involved: visual/nervous (sensory), reproductive (male infertility), renal/urinary, respiratory (if PCD features), and the visceral situs of cardiovascular/digestive systems.

Tissue and cell level: Neural retina — rod photoreceptors (CL:0000604) and cone photoreceptors (CL:0000573) are the primary targets; motile ciliated cells of node, airway, and reproductive tract; renal tubular epithelium. Patient fibroblasts (in vitro) show shortened cilia and reduced proliferation (PMID: 36507858).

Subcellular level: The connecting cilium / basal body (GO:0036064) is the central compartment. UniProt/GO also annotate ARL2BP to centrosome (GO:0005813), spindle (GO:0005819), midbody (GO:0030496), cytosol (GO:0005829), nucleoplasm (GO:0005654), and mitochondrial intermembrane space (GO:0005758)/matrix (GO:0005759) — reflecting moonlighting roles.

Localization / lateralization: Retinal involvement is bilateral and roughly symmetric; situs inversus is a whole-body laterality reversal (mirror-image organ arrangement); renal agenesis reported as unilateral.

8. Temporal Development

Onset: Situs inversus and renal/laterality anomalies are congenital. Retinal disease is typically young-adult onset: photophobia often first at ~20 years, nyctalopia and central vision loss by ~30 years (PMID: 38649918). Onset pattern is insidious and chronic.

Progression: Chronic, lifelong, and progressive but can be slow — one patient retained useful residual vision at 63 with slow progression over a 5-year window (PMID: 38649918). Typical RP staging applies: early (night blindness, mid-peripheral field loss) → intermediate (ring scotoma, constricted fields) → advanced (tunnel vision) → end-stage (central/legal blindness). Situs inversus is stable and non-progressive.

Patterns: No remissions; no relapsing–remitting course. The therapeutic window for any future retinal gene therapy is early disease while viable photoreceptors remain — an important critical-period consideration.

9. Inheritance and Population

Inheritance: Autosomal recessive. Biallelic ARL2BP variants; reported families are consanguineous with homozygous alleles.

Penetrance / expressivity: Retinal disease appears fully penetrant in biallelic carriers; situs inversus shows incomplete penetrance / variable expressivity ("with or without"), reflecting the stochastic left–right axis determination by nodal cilia. Extra-ocular features (renal, olfactory, fertility) are variably expressed.

Founder effects / consanguinity: Strong consanguinity contribution; homozygous variants in geographically distinct families (Middle East, China, Italy, Pakistan). No genetic anticipation, germline mosaicism, or repeat-expansion mechanism.

Epidemiology: Retinitis pigmentosa overall has a worldwide prevalence of ~1:4,000 (~100,000 affected in the USA), with 20–30% of cases syndromic (PMID: 29597005): "RP is a leading cause of visual disability, with a worldwide prevalence of 1:4000. Although the majority of RP cases are non-syndromic, 20-30% of patients with RP also have an associated non-ocular condition." ARL2BP-related RP (RP66) is an ultra-rare subtype — only a handful of families reported worldwide. In a consanguineous Pakistani IRD cohort it accounted for 1 of 72 families (1.4%) (PMID: 40384762): "…1/72(1.38%) … in … retinitis pigmentosa with situs inversus … segregated families."

Sex ratio: Retinal disease affects both sexes; the infertility phenotype is specific to males. Carrier frequency: Not precisely established; expected very low outside consanguineous populations.

10. Diagnostics

Ophthalmic evaluation (core): Full-field electroretinogram (ERG) shows markedly reduced or absent rod and cone responses; fundus shows bone-spicule pigmentation and optic-disc pallor; OCT and fundus autofluorescence (FAF) show progressive loss of outer retinal layers (PMID: 29597005): "Photoreceptor function measured with an electroretinogram is markedly reduced or even absent. Optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging show a progressive loss of outer retinal layers." ARL2BP cases were additionally assessed with full-field stimulus threshold testing and multimodal imaging (PMID: 38649918).

Molecular genetic testing (definitive): Next-generation sequencing — targeted IRD capture panels (e.g., a 344-gene panel, PMID: 40384762), whole-exome, or whole-genome sequencing — with ACMG/AMP variant interpretation and Sanger segregation confirmation. Homozygosity mapping is valuable in consanguineous families (PMID: 23849777).

Extra-ocular workup: Chest X-ray/abdominal imaging/echocardiography to detect situs inversus; semen analysis for oligo-/asthenozoospermia; renal ultrasound for agenesis/microcysts; olfactory testing where indicated.

Differential diagnosis: Other syndromic retinal ciliopathies — Usher syndrome, Bardet–Biedl syndrome, Senior–Løken syndrome, and other RP-with-situs-inversus/PCD overlaps; distinguished by gene panel and by the specific extra-ocular pattern. Screening: Cascade genetic testing of at-risk relatives and carrier testing in consanguineous families once the familial variant is known.

11. Outcome / Prognosis

Survival / mortality: The disorder is not life-limiting in itself. Situs inversus totalis is typically asymptomatic and compatible with normal lifespan. Life expectancy is generally normal unless significant primary-ciliary-dyskinesia respiratory disease is present.

Morbidity / function: The principal morbidity is progressive, irreversible vision loss leading to legal blindness in advanced disease — a major disability outcome with substantial QoL impact. Male infertility is a reproductive-health morbidity. Recovery potential: None with current therapy; photoreceptor loss is irreversible.

Disease course / complications: Chronic, progressive vision loss; cystoid macular edema and cataract can complicate RP generally; PCD-associated respiratory infections if motile-cilia airway disease is present.

Prognostic factors: Age at onset, rate of ERG/field decline, and residual outer-retinal structure on OCT predict visual outcome. Some ARL2BP patients show relatively slow progression with preserved vision into the seventh decade (PMID: 38649918).

12. Treatment

There is no proven disease-modifying therapy. A 2020 Cochrane review of vitamin A and DHA/fish oils concluded evidence for slowing RP progression is limited/uncertain (PMID: 32573764): "At this time, there is no proven therapy for RP."

Supportive / rehabilitative care (mainstay): Visual aids, orientation and mobility training, and nutritional supplementation provide only symptomatic relief and do not halt progression (PMID: 40731809): "While current management is largely supportive-relying on visual aids, orientation training, and nutritional supplementation-these interventions offer only symptomatic relief and do not halt disease progression." (NCIT: Supportive Care; Low Vision Aid.)

Not applicable: The only approved retinal gene therapy, voretigene neparvovec (Luxturna), is specific to biallelic RPE65 mutations and does not apply to ARL2BP (PMID: 37762059).

Investigational: AAV gene-replacement, RNA-based, and CRISPR/Cas9 strategies are advancing for RP broadly but remain investigational for ARL2BP (PMID: 40869487, PMID: 40731809). ARL2BP's small coding sequence makes it a favorable candidate for AAV gene replacement in principle.

Management of extra-ocular features: Situs inversus totalis usually needs no treatment; PCD-type respiratory disease (if present) needs airway clearance/antibiotics; male infertility may be addressed with assisted reproduction (ICSI). (NCIT: Assisted Reproductive Technology; Intracytoplasmic Sperm Injection.)

Pharmacogenomics / personalized medicine: No genotype-guided pharmacotherapy exists; future precision approaches would be gene-replacement or variant-specific (e.g., splice-modulating ASOs for splice-site alleles).

13. Prevention

Being monogenic and recessive, prevention is genetic/reproductive, not lifestyle-based.

• Primary prevention: Not achievable by risk-factor modification. Genetic counseling for consanguineous families and known carriers; recurrence risk is 25% per pregnancy for two carrier parents.
• Carrier / cascade screening: Test at-risk relatives once the familial ARL2BP variant is identified.
• Reproductive options: Prenatal diagnosis and preimplantation genetic testing (PGT-M) for couples known to carry pathogenic ARL2BP variants.
• Secondary/tertiary prevention: Early ophthalmic monitoring to manage complications (cataract, macular edema), low-vision rehabilitation, and airway surveillance where PCD features exist. No immunization or public-health intervention is relevant.

14. Other Species / Natural Disease

Orthologs (NCBI Gene): mouse Arl2bp (GeneID 107566), rat Arl2bp (GeneID 498910), zebrafish arl2bp (GeneID 393976). A functional ARL2BP homolog is present and essential in ciliate protozoa, where RNAi is lethal and disrupts cortical microtubules (PMID: 40432967): "RNAi of ARL2BP and DYNLRB2 increased mortality, reduced motility, and disrupted cortical microtubule organization" — demonstrating deep evolutionary conservation of ARL2BP's ciliary/microtubule role.

Natural disease in other species: No well-characterized naturally occurring ARL2BP disease is documented in companion animals or wildlife (OMIA entries not established for this specific gene–disease pair). Comparative biology: The conserved ciliary function across mammals, fish, and protozoa underpins the utility of cross-species models. Zoonotic potential: None (non-transmissible genetic disease).

15. Model Organisms

Primary model — Arl2bp-knockout mouse: A knockout mouse recapitulates key human features (PMID: 29718757): "we generated a knockout (KO) mouse model for ARL2BP, a ciliary protein linked to retinitis pigmentosa. The KO mice display an early and progressive reduction in visual response." Structurally: "we observed disorganization of the photoreceptor OS, with vertically aligned disks and shortened axonemes … ciliary doublet microtubule (MT) structure was also impaired, displaying open B-tubule doublets, paired with loss of singlet MTs."

• Phenotype recapitulation: High for the retinal phenotype — early, progressive ERG decline; disorganized outer segments; connecting-cilium/axoneme and doublet-microtubule defects.
• Applications: Studying outer-segment morphogenesis, ciliary microtubule assembly, ARL2/ARL3 trafficking, and as a preclinical platform for gene-replacement testing.
• Limitations: Mouse retinal architecture (rod-dominant, no macula) limits translation of central-vision outcomes; extent to which the model reproduces situs inversus/laterality and fertility phenotypes is less fully characterized.

In vitro models: Patient-derived fibroblasts show reduced proliferation and shortened cilia (PMID: 36507858), providing a cellular ciliogenesis assay. Zebrafish and ciliate systems offer additional conserved platforms for ciliary-function studies.

Mechanistic Model / Interpretation

 ARL2BP biallelic LoF mutation (splice / frameshift / p.Met45Arg)
              │
              ▼
 Loss/dysfunction of ARL2BP protein
              │
              ▼
 Failure to localize at basal body / cilium-associated centriole
   (p.Met45Arg abolishes basal-body localization; loses ARL2 binding)
              │
              ▼
 Disrupted ARL2 / ARL3 GTPase cycle  (ARL2BP = ARL2-GTP effector + ARL3 co-GEF)
              │
              ▼
 Defective ARL3–PDE6D ciliary trafficking of prenylated proteins (PDE6, GRK1)
   + defective axoneme / doublet-microtubule assembly
              │
        ┌─────┴───────────────────────────────┐
        ▼ (sensory cilium)                     ▼ (motile cilia)
 Disorganized photoreceptor outer segment   Nodal cilia → SITUS INVERSUS (~50%)
 (vertical disks, short axoneme,            Sperm flagella → male infertility
  open B-tubules, lost singlet MTs)         Airway cilia → PCD-type disease
        │                                    Renal cilia → agenesis/microcysts
        ▼                                    Olfactory cilia → anosmia
 Progressive rod & cone death
        │
        ▼
 RETINITIS PIGMENTOSA (nyctalopia → field loss → central vision loss)

Upstream vs downstream: The mutation and ARL2BP loss are upstream; the ARL2/ARL3 cycle and PDE6D trafficking are the central molecular node; outer-segment malformation and photoreceptor death are downstream retinal outcomes; laterality/fertility/renal/olfactory features are parallel downstream consequences in motile-cilia tissues. The "with or without situs inversus" naming captures the branch point: the same molecular lesion produces retinal disease in all patients but laterality defects only when nodal-cilia motility is sufficiently disrupted during embryogenesis.

Evidence Base

Evidence source types: Human clinical/genetic (23849777, 36507858, 38649918, 40384762, 29597005); model organism (29718757 mouse; 40432967 ciliate); in vitro (36507858 fibroblasts; 33438581 biochemistry; 25422369); systematic review/therapeutic (32573764, 40731809, 37762059, 40869487).

Limitations and Knowledge Gaps

• Ultra-rare with small n. The entire literature rests on a handful of families/probands. Penetrance estimates (especially the ~50% figure for situs inversus) are approximate, and genotype–phenotype correlations are underpowered.
• No formal epidemiology. No registry-based prevalence/incidence for the ARL2BP subtype; figures derive from overall RP prevalence and single-cohort proportions.
• QoL and natural-history data are absent for this specific subtype; progression rate estimates come from isolated case follow-up.
• Motile-cilia phenotype incompletely characterized. The mechanistic link between ARL2BP loss and nodal/sperm/airway ciliary dysfunction is inferred from ciliopathy biology and case observations more than direct experiment; airway/PCD burden is not systematically documented.
• Modifier and epigenetic factors unexplored; explanation for variable situs inversus penetrance is mechanistic/stochastic rather than empirically mapped.
• No therapy validated — gene replacement is promising in principle but untested in ARL2BP models.

Proposed Follow-up Experiments / Actions

1. International case registry / GeneMatcher recruitment to aggregate ARL2BP patients, refine penetrance of situs inversus, fertility, renal and olfactory involvement, and establish natural-history/progression rates.
2. AAV-ARL2BP gene-replacement proof-of-concept in the Arl2bp-KO mouse — the small coding sequence fits AAV capacity; measure ERG rescue and outer-segment/axoneme restoration.
3. Splice-modulating ASO testing for recurrent splice-acceptor alleles (c.101-1G>C, c.294-1G>C) in patient fibroblasts/iPSC-derived retinal organoids.
4. iPSC-derived retinal organoids and multiciliated-airway cultures from patients to model both sensory- and motile-cilia branches and to quantify trafficking of prenylated cargo (PDE6, GRK1).
5. Systematic PCD/airway and fertility phenotyping across the cohort to define the motile-cilia disease burden and inform surveillance guidelines.
6. Structural/biochemical dissection of the ARL2BP–ARL2/ARL3 co-GEF interface to enable variant-specific functional classification of VUS in ClinVar.

Report compiled from 9 confirmed findings and 21 reviewed papers across a 5-iteration autonomous investigation. Evidence types and PMIDs are indicated throughout; ontology term suggestions (HPO, GO, CL, UBERON, NCIT) are embedded per section.